Covid 19 Clinical Trials

To capture the natural history of COVID-19 associated olfactory dysfunction as measured by two patient reported outcome measures (SNOT-22, QOD-NS) and a 6-week BSIT with a comparison to an intervention arm receiving daily omega-3 supplements.

NCT04495816 Anosmia Covid19 Drug: Omega-3 Fatty Acid Supplement Drug: Placebo/Control

MeSH:Olfaction Disorders

HPO:Anosmia

Primary Outcomes

Description: Brief Smell Identification Test (BSIT) is a 12-item instrument, full range score from 0 to 12, higher score indicates better olfactory performances.

Measure: Brief Smell Identification Test (BSIT)

Time: Week 0

Description: Brief Smell Identification Test (BSIT) is a 12-item instrument, full range score from 0 to 12, higher score indicates better olfactory performances.

Measure: Brief Smell Identification Test (BSIT)

Time: 6 weeks after beginning to take supplements

Secondary Outcomes

Description: The modified Brief Questionnaire of Olfactory Dysfunction - Negative Statements (QOD-NS) survey is a 17-item instrument, each item graded on a scale from 0 to 3, with total scale range from 0 to 51. Higher score indicates better olfactory-specific quality of life (QOL).

Measure: Modified Brief Questionnaire of Olfactory Dysfunction (mQOD-NS)

Time: 1 week after softgel initiation

Measure: Modified Brief Questionnaire of Olfactory Dysfunction (mQOD-NS)

Time: 2 weeks after softgel initiation

Measure: Modified Brief Questionnaire of Olfactory Dysfunction (mQOD-NS)

Time: 4 weeks after softgel initiation

Measure: Modified Brief Questionnaire of Olfactory Dysfunction (mQOD-NS)

Time: 6 weeks after softgel initiation

Description: Sino-Nasal Outcome Test (SNOT-22) is a 22-item instrument, total scale range from 0 to 110, higher score indicates more severe QOL impact.

Measure: Sinonasal Outcomes Test (SNOT-22)

Time: 1 week after softgel initiation

Description: Sino-Nasal Outcome Test (SNOT-22) is a 22-item instrument, total scale range from 0 to 110, higher score indicates more severe QOL impact.

Measure: Sinonasal Outcomes Test (SNOT-22)

Time: 2 weeks after softgel initiation

Description: Sino-Nasal Outcome Test (SNOT-22) is a 22-item instrument, total scale range from 0 to 110, higher score indicates more severe QOL impact.

Measure: Sinonasal Outcomes Test (SNOT-22)

Time: 4 weeks after softgel initiation

Description: Sino-Nasal Outcome Test (SNOT-22) is a 22-item instrument, total scale range from 0 to 110, higher score indicates more severe QOL impact.

CovidResearchTrials by Shray Alag

Covid 19 Research using Clinical Trials (Home Page)

Placebo/ControlWiki

Developed by Shray Alag

Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (1)

Correlated MeSH Terms (1)

Correlated HPO Terms (1)

Clinical Trials

1 COVID-19 Anosmia Study

NCT04495816 Anosmia Covid19 Drug: Omega-3 Fatty Acid Supplement Drug: Placebo/Control

MeSH:Olfaction Disorders

HPO:Anosmia

Primary Outcomes

Secondary Outcomes

Related HPO nodes (Using clinical trials)

HP:0000458: Anosmia

Genes 67

Protein Mutations 0

SNP 0